SubsidieMeestersAlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach
Alkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028.
Projectdetails
Introduction
Alkion, a revolutionary biotech company, is developing a breakthrough biorefinery to produce top quality active pharmaceutical ingredients (API) and extracts in plants in a sustainable and cost-effective way. Our core technology combines our disruptive patented automated bioreactor - AlkaBurst2.0 - with unique know-how on gene expression methods, culture media, and extraction. Our process offers high productivity and a low carbon footprint.
Industry Challenges
The pharma industry is carbon intensive with recurring problems of quality and safety. Moreover, many critical APIs are outsourced to Asia to cut costs.
Solution Overview
AlkaBurst2.0 allows for local standardized production of safe and clean APIs in its automated process, saving:
- 75% time
- 80% space
- 95% electricity
- 98% water
Validation and Funding
We first validated the production for Covid-19 natural vaccine adjuvants QS21/7, cannabinoids, and certain recombinant proteins for the urgent market demand.
Financial Projections
We need €7.5M to build and validate our pilot and expect to generate €125M in revenue by 2028, creating 105 jobs.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.586.937 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ALKION BIOINNOVATIONSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Scalable and Eco-friendly BioproductionCore Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins. | EIC Accelerator | € 1.153.390 | 2023 | Details |
Disrupting the food ingredient and protein markets: a breakthrough technology for large-scale microalgae cultivation.Arborea aims to develop a revolutionary bioreactor for large-scale microalgae production to meet rising protein demand sustainably and affordably by 2050. | EIC Accelerator | € 2.348.873 | 2022 | Details |
Transforming Molecular Diagnostics through NanoTechnologyAltratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification. | EIC Accelerator | € 2.499.999 | 2024 | Details |
The scale-up of the BioMilk platform: The revolutionary approach to manufacturing of biopharmaceuticalsBio-Sourcing aims to revolutionize biosimilar production with its BioMilk platform, leveraging CRISPR-engineered goats for cost-effective, sustainable manufacturing and securing licensing deals by 2027. | EIC Accelerator | € 2.475.890 | 2024 | Details |
First of a kind bio n-butanol industrial facilityCatalyxx aims to scale its patented biorefinery technology to produce sustainable bio-based chemicals, reducing carbon footprint and offering alternatives to fossil feedstocks. | EIC Accelerator | € 2.495.625 | 2024 | Details |
Scalable and Eco-friendly Bioproduction
Core Biogenesis aims to become the European leader in plant-based biomanufacturing by 2025, using a novel process to significantly enhance yield and reduce costs for producing pharmaceutical proteins.
Disrupting the food ingredient and protein markets: a breakthrough technology for large-scale microalgae cultivation.
Arborea aims to develop a revolutionary bioreactor for large-scale microalgae production to meet rising protein demand sustainably and affordably by 2050.
Transforming Molecular Diagnostics through NanoTechnology
Altratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification.
The scale-up of the BioMilk platform: The revolutionary approach to manufacturing of biopharmaceuticals
Bio-Sourcing aims to revolutionize biosimilar production with its BioMilk platform, leveraging CRISPR-engineered goats for cost-effective, sustainable manufacturing and securing licensing deals by 2027.
First of a kind bio n-butanol industrial facility
Catalyxx aims to scale its patented biorefinery technology to produce sustainable bio-based chemicals, reducing carbon footprint and offering alternatives to fossil feedstocks.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development & demonstration of low environmental impact innovation and optimization practices in pharma productionLIFE-GREENAPI aims to revolutionize API production in Europe by implementing flow-chemistry to enhance sustainability, reduce environmental impact, and support the pharmaceutical sector's decarbonization efforts. | LIFE Standar... | € 1.516.536 | 2023 | Details |
Bioraffinage van eiwitstrengen uit biomassa tbv. Pharma en (bulk)chemieHet project richt zich op het ontwikkelen van processen voor het winnen van eiwitten uit biomassa, gericht op duurzame toepassingen in de chemie en farmacie, ter ondersteuning van de groeiende vraag naar eiwitten. | Mkb-innovati... | € 20.000 | 2021 | Details |
Continuous Digitalized Processes for Producing BiopharmaceuticalsDeveloping a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Sensoriek en Vloeistofadditie MicrobioreactorenDit project ontwikkelt nieuwe sensoriek en vloeistofadditiesystemen voor microbioreactors om de biofarmaceutische ontwikkeling van medicijnen te versnellen en kosten te verlagen. | Mkb-innovati... | € 350.000 | 2015 | Details |
Microbiële cel fabriekjes voor de productie van OxytetracyclineEV Biotech ontwikkelt microbiële cel fabriekjes voor duurzame productie van het antibioticum Oxytetracycline, waarbij digitale modellering kosten en tijd reduceert en milieueffecten minimaliseert. | Mkb-innovati... | € 20.000 | 2020 | Details |
Development & demonstration of low environmental impact innovation and optimization practices in pharma production
LIFE-GREENAPI aims to revolutionize API production in Europe by implementing flow-chemistry to enhance sustainability, reduce environmental impact, and support the pharmaceutical sector's decarbonization efforts.
Bioraffinage van eiwitstrengen uit biomassa tbv. Pharma en (bulk)chemie
Het project richt zich op het ontwikkelen van processen voor het winnen van eiwitten uit biomassa, gericht op duurzame toepassingen in de chemie en farmacie, ter ondersteuning van de groeiende vraag naar eiwitten.
Continuous Digitalized Processes for Producing Biopharmaceuticals
Developing a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine.
Sensoriek en Vloeistofadditie Microbioreactoren
Dit project ontwikkelt nieuwe sensoriek en vloeistofadditiesystemen voor microbioreactors om de biofarmaceutische ontwikkeling van medicijnen te versnellen en kosten te verlagen.
Microbiële cel fabriekjes voor de productie van Oxytetracycline
EV Biotech ontwikkelt microbiële cel fabriekjes voor duurzame productie van het antibioticum Oxytetracycline, waarbij digitale modellering kosten en tijd reduceert en milieueffecten minimaliseert.